<DOC>
	<DOCNO>NCT01836341</DOCNO>
	<brief_summary>The purpose Phase I study test safety combine afatinib standard chemotherapy radiation . The drug afatinib give chemotherapy radiation therapy shrink tumor evaluate afatinib affect patient . This study test safety afatinib different dose level combine chemotherapy drug cisplatin carboplatin , pemetrexed . These treatment give radiation treatment drug afatinib continue chemotherapy radiation .</brief_summary>
	<brief_title>Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Unresectable inoperable , stage III locoregional recurrence without evidence distant , metastatic disease Pathologic confirmation NSCLC MSKCC Documentation sensitize EGFR mutation Age ≥ 18 year No contraindication definitive thoracic radiation therapy concurrent chemotherapy Adequate organ function define : Calculated creatinine clearance≥ 45 mL/min ( CockcroftGault ) Total bilirubin le 1.5 x ULN ( unless know Gilbert 's disease ) AST/ALT le 3 x ULN Absolute neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Women childbearing age must negative blood pregnancy test Men woman childbearing potential must willing use effective contraception treatment least 3 month Prior chemotherapy radiation therapy lung cancer ( history prior lung cancer treat deeded inactive clinician acceptable ) Ineligible cisplatin carboplatin per medical oncologist Ineligible pemetrexed per medical oncologist Greater minimal , exudative , malignant pleural effusion Calculated creatinine clearance Cockcroft &amp; Gault method ≤45 ml/min Unstable congestive heart failure Ejection fraction &lt; 50 % assessed MUGA echocardiogram Interstitial lung disease Patient require ongoing treatment potent inhibitor ( cyclosporin , erythromycin , ketoconazole , itraconazole , quinidine , phenobarbital quinidine , ritonavir , valspodar , verapamil ) inducer Pgp ( St. John 's wort rifampin ) Women breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Afatinib</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Radiation therapy</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>12-279</keyword>
</DOC>